Trial reportJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2013
Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
Trial report in Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Fingolimod for relapsing-remitting multiple sclerosis.The Cochrane database of systematic reviews · 2016Pooled it
- Optical coherence tomography biomarkers and visual functions in tuberculous meningitis: an observational study.International ophthalmology · 2025Observational
- The Effects of Disease-Modifying Therapies on Optic Nerve Degeneration in Multiple Sclerosis.European journal of neurology · 2025Review
- Evaluation of optical coherence tomography angiography findings in patients with multiple sclerosis.Indian journal of ophthalmology · 2021Article
- Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.International ophthalmology · 2019Article
- Acute hypertensive uveitis as the first presentation of multiple sclerosis.Indian journal of ophthalmology · 2019Article
- Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Observational
- Evaluating optic nerve diameter as a possible biomarker for disability in patients with multiple sclerosis.Neuropsychiatric disease and treatment · 2019Article
- Benign Multiple Sclerosis is Associated with Reduced Thinning of the Retinal Nerve Fiber and Ganglion Cell Layers in Non-Optic-Neuritis Eyes.Journal of clinical neurology (Seoul, Korea) · 2015Article
- Retinal nerve fiber layer sector-specific compromise in relapsing and remitting multiple sclerosis.eNeurologicalSci · 2015Article
- Vision and vision-related outcome measures in multiple sclerosis.Brain : a journal of neurology · 2015Review
- Optical coherence tomography for retinal imaging in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2014Article
- Comparative skull analysis suggests species-specific captivity-related malformation in lions (Panthera leo).PloS one · 2014Article
- Application of Optical Coherence Tomography in the Detection and Classification of Cognitive Decline.Journal of current glaucoma practiceReview
- The role of optical coherence tomography in therapeutics and conditions, which primarily have systemic manifestations: a narrative review.Therapeutic advances in ophthalmologyReview
- Discriminative Abilities of Macular and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis and Optic Neuritis.Journal of current ophthalmologyArticle
- Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundPatients with multiple sclerosis (MS) demonstrate thinning of peripapillary retinal nerve fiber layer (RNFL) and decreased macular volume as measured by optical coherence tomography (OCT). To our knowledge, there are no previous reports from a large MS OCT database with strict quality control measures that quantitate RNFL and macula in patients with relapsing-remitting multiple sclerosis.
methodsThe University of California Davis OCT Reading Center gathered OCT data at baseline as part of the North American phase 3 trial of fingolimod (Gilenya). Average RNFL thickness (RNFLT) and macular volume (TMV) were measured using time domain OCT (TD-OCT). RNFL quadrants, clock hours, and macular subfields were included. With strict quality control and accounting for signal strength differences, scans were categorized as "reduced" or "not reduced" for each field, based on being less than 5th percentile for age-matched controls derived from the normative database in the scanner software. Patients were deemed "abnormal" if at least 1 eye had reduced values for a given parameter. Patients with abnormalities in corresponding RNFL and macular subfields were compared by cross-tabulation.
resultsThe TD-OCT data were prospectively collected from 939 of the 1,083 trial patients, 712 of whom met all final quality and data inclusion criteria. Of the final cohort, 242 (34.0%) demonstrated reduced (less than 5th percentile) average RNFLT in at least 1 eye. One hundred seventy-eight (25.0%) patients had reduced TMV. One hundred twenty-eight (18.0%) demonstrated both reduced TMV and RNFLT in the same eye, whereas 42 (5.8%) had reduced TMV and RNFLT in both eyes. Of the 242 patients with reduced average RNFL thickness, 128 (52.9%) also had reduced TMV. Fifty patients had reduced TMV in the absence of reduced RNFLT in at least 1 eye, a cohort prevalence of 7.0%. Quadrant and subfield analysis showed a predominance of temporal and inferior RNFL thinning, with inferior macular thinning corresponding best to RNFL thinning.
conclusionRNFL and macular thinning/volume loss is common at baseline in relapsing-remitting multiple sclerosis, as measured by TD-OCT. When the RNFL is thin, the macular volume is reduced in more than half of the patients. There is a population of reduced TMV without any reduction in RNFLT. Documenting the prevalence and distribution of these structural abnormalities supports recent reports and suggests new retinal areas to probe for functional vision changes in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.